Loading
institutionsInstitution
National Healthcare Security Administration
The NHSA runs China's public health insurance and negotiates once a year which new cancer drugs are reimbursed, and at what price, through the National Reimbursement Drug List.
Also called: NHSA国家医疗保障局
Overview
Created in 2018 to merge the urban employee, urban resident and rural insurance schemes, the NHSA administers basic medical insurance for more than 1.3 billion people and the National Reimbursement Drug List (NRDL). Since 2017 (15 targeted anticancer drugs, average 48.9% cut in cost per defined daily dose) and the dedicated 2018 oncology round (17 drugs), it has run annual price negotiations in which manufacturers accept steep discounts, typically more than half, for national reimbursement; renewals are renegotiated and a dual-channel policy (2021) lets designated pharmacies dispense listed drugs when hospitals do not stock them. It also runs volume-based procurement of generics and the DRG payment reform.
Location
Beijing, CN
Type
government
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#382 · 16 points (0 Newsweek + 0 NCI + 16 from 8 linked objects) · ranking
- National Reimbursement Drug List annual negotiation
- Dual-channel pharmacy access for negotiated drugs
- Volume-based procurement
- DRG/DIP payment reform
observationalJournal of global health 202243 citations
Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China: A controlled interrupted time series study
One institution page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
observationalBMJ global health 202159 citations
The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China
One institution page on OnCo cites this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing page listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
Similar pages
- PersonSaijuan Chen
Shares Zhu Chen and the tag china.
- TrialORIENT-11
Shares National Medical Products Administration / Center for Drug Evaluation, Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag china.
- TrialRELIANCE
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag china.
- TreatmentRelmacabtagene autoleucel
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag china.
- CompanyJW Therapeutics
Shares Prices and value and the tag china.
- CompanyShanghai Junshi Biosciences
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag china.
- CompanyInnovent Biologics
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag china.
- TreatmentSintilimab
Shares Global access and affordability roadmap: essential medicines and generics → biosimilars and frugal trials → reliance, pooling and homegrown innovation and the tag china.